FDA Acts to Support Development of Potential Gene Therapy, TSHA-102
The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to TSHA-102, a potential gene therapy for Rett syndrome. Taysha Gene Therapies, the treatment’s developer, plans to submit an investigational new drug application to the FDA in 2021 to…